ロード中...
Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming
The worldwide prevalence of non-alcoholic fatty liver disease is around 25%, and that of nonalcoholic steatohepatitis (NASH) ranges from 1.5% to 6.45%. Patients with NASH, especially those with fibrosis, are at higher risk for adverse outcomes such as cirrhosis and liver-related mortality. Although...
保存先:
| 出版年: | Diabetes Metab J |
|---|---|
| 第一著者: | |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Korean Diabetes Association
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7643594/ https://ncbi.nlm.nih.gov/pubmed/33115209 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4093/dmj.2020.0115 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|